PRS27 Incorporating Heterogeneity in Risk for Infection and Disease in Cost-Effectiveness of Preventative Strategies in Older Adults

Comment on Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium. Vaccines 2023, 11, 990

“…There are a few other strange elements observed in the calculations made. The authors conducted a pooled analysis of the age group 60+ even though there is strong heterogeneity present, e.g., age, sex, co-morbidity spread, and location, factors which are all involved in varied exposures to the infection [20]. Their model structure (Figure 1) shows a population overall mortality impact separated from the vaccine and the no-vaccine branches, which is bizarre if the vaccine arm avoids more specific deaths than the no-vaccine arm.…”